       Document 0028
 DOCN  M9620028
 TI    Suppression of infectious virus spread to the liver by foscarnet
       following lethal infection of acyclovir-resistant herpes simplex virus
       type 2 in mice.
 DT    9602
 AU    Li YY; Minagawa H; Tanaka S; Mori R; Department of Virology, Faculty of
       Medicine, Kyushu University,; Fukuoka, Japan.
 SO    Antiviral Res. 1995 May;27(1-2):111-21. Unique Identifier : AIDSLINE
       MED/96075699
 AB    Patients with the acquired immune deficiency syndrome (AIDS)
       occasionally develop hepatitis, pneumonia or esophagitis due to herpes
       simplex virus type 2 (HSV-2) infection. HSV hepatitis is a rare but
       serious complication in liver transplantation. Acyclovir-resistant HSV
       strains may emerge in immunocompromised patients. Following
       intraperitoneal inoculation, HSV-2 induces necrotizing hepatitis in
       mice. We studied the virus spread and mortality following
       intraperitoneal inoculation of HSV-2 RK (an acyclovir-resistant
       recombinant virus with altered thymidine kinase activity) as compared to
       its parent virus 8620K. Neither the 50% lethal dose (LD50) nor the
       average survival time was significantly different between the two
       strains. Parenteral acyclovir treatment was found to be effective
       against 8620K but not RK infection. Parenteral foscarnet treatment was
       effective against both RK and 8620K, and also inhibited the spread of
       either virus to the liver, spinal cord and brain. Peroral foscarnet
       administration was found to prevent the virus growth in the liver.
 DE    Acyclovir/PHARMACOLOGY  Animal  Arabinonucleosides/PHARMACOLOGY
       Brain/VIROLOGY  Cercopithecus aethiops  Drug Resistance, Microbial
       Foscarnet/*PHARMACOLOGY  Hepatitis, Viral, Animal/*DRUG THERAPY/VIROLOGY
       Herpes Genitalis/*DRUG THERAPY  Herpesvirus 2, Human/*DRUG EFFECTS
       Human  Injections, Intraperitoneal  Lethal Dose 50  Mice  Mice, Inbred
       C3H  Phosphonoacetic Acid/PHARMACOLOGY  Support, Non-U.S. Gov't
       Thymidine/ANALOGS & DERIVATIVES/PHARMACOLOGY  Vero Cells
       Vidarabine/PHARMACOLOGY  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

